Difference between revisions of "The Future of R&D in Pharmaceutical Industry in 2025"
Ruthdonners (talk | contribs) m |
Ruthdonners (talk | contribs) |
||
| Line 7: | Line 7: | ||
<br> | <br> | ||
Work under construction. | Work under construction. | ||
<br> | <br> | ||
Scenarios | '''Scenarios''' | ||
<br> | <br><br> | ||
'''Driving forces'''<br><br> | |||
''Edited existing ones''<br><br> | |||
• [[Increasing potential to grow based on new available technology]] | |||
• [[Struggling old world economy]] | |||
• [[Increasing Empowerment of Consumers in Healthcare System]] | |||
• [[Continuously growing demand for new medical applications]] | |||
• [[The increasing gap between developed, emerging and poor economies]] | |||
• [[The increasing globalization of markets]] | |||
• [[Power of the United Nations]] | |||
• [[Legal Restrictions for Biotech increasing in certain countries, decreasing in others]] | |||
<br><br>''two more will be added'' | |||
''Added new ones''<br><br> | |||
• [[IP rights]] | |||
• [[Logistics/Distribution]] | |||
• [[Illnesses of global importance/Pandemics]] | |||
• [[Research budget in pharmaceutical industry]] | |||
• [[Effect of development of health care system in emerging market countries to existing pharmaceutical industry]] | |||
• [[Unification of regulatory approval]] | |||
• [[Competitiveness through innovation in biotechnology]] | |||
• [[New business models for pharmaceutical industry]] | |||
<br><br>''two more will be added'' | |||
Revision as of 19:50, 10 September 2009
EMBA09 team:
Murat Akguc
Ruth Donners
Peter Friedl
Susan Liu
Eva Stjernschantz
Work under construction.
Scenarios
Driving forces
Edited existing ones
• Increasing potential to grow based on new available technology
• Struggling old world economy
• Increasing Empowerment of Consumers in Healthcare System
• Continuously growing demand for new medical applications
• The increasing gap between developed, emerging and poor economies
• The increasing globalization of markets
• Power of the United Nations
• Legal Restrictions for Biotech increasing in certain countries, decreasing in others
two more will be added
Added new ones
• IP rights
• Logistics/Distribution
• Illnesses of global importance/Pandemics
• Research budget in pharmaceutical industry
• Effect of development of health care system in emerging market countries to existing pharmaceutical industry
• Unification of regulatory approval
• Competitiveness through innovation in biotechnology
• New business models for pharmaceutical industry
two more will be added